

# Research Progress on the Relationship between Ferroptosis and Insulin Resistance

Lujing Yu<sup>1,2,a</sup>, Guihong Huang<sup>3,4,5,6,b,\*</sup>

<sup>1</sup>Lingui Clinical College, Guilin Medical University, Guilin, Guangxi, 541199, PR China

<sup>2</sup>College of Pharmacy, Guilin Medical University, Guilin, Guangxi, 541199, PR China

<sup>3</sup>Department of Pharmacy, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, 541199, PR China

<sup>4</sup>Guangxi Health Commission Key Laboratory of Glucose and Lipid Metabolism Disorders, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, 541199, PR China

<sup>5</sup>Guangxi Key Laboratory of Diabetic Systems Medicine, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, 541199, PR China

<sup>6</sup>Guangxi Key Laboratory of Drug Discovery and Optimization, Guangxi Engineering Research Center for Pharmaceutical Molecular Screening and Druggability Evaluation, School of Pharmacy, Guilin Medical University, Guilin, Guangxi, 541199, PR China

<sup>a</sup>1047155145@qq.com, <sup>b</sup>guihonghuang666@163.com

\*Corresponding author

**Abstract:** Insulin resistance (IR) is a core mechanism leading to obesity and metabolic dysfunction of diabetes, and is the main cause of type 2 diabetes (T2DM). However, the etiology and mechanism of IR are very complex, which has not been clarified yet. Ferroptosis is a new type of iron dependent cell death, which is different from apoptosis, necrosis, autophagy and other typical cell death. It is not clear whether there is a direct relationship between Ferroptosis and IR. At present, only a few studies have explored the relationship between Ferroptosis and T2DM. The article starts from the mechanism of the two, reveals the possible relationship between them, so as to increase the understanding of IR and Ferroptosis, and hopes to lay a foundation for further clarifying the mechanism of insulin resistance.

**Keywords:** Insulin resistance, Ferroptosis, Pathogenesis, Oxidative stress, Iron overload

## 1. Introduction

According to the report of the International Diabetes Federation (IDF) in 2021[1], the number of DM patients will continue to grow year by year, and is expected to increase to 783.2 million by 2045, reaching 12.2% of the world's total population, of which Type 2 Diabetes (T2DM) can account for more than 90%. IR is a core mechanism leading to metabolic dysfunction in obesity and diabetes, and is the main cause of T2DM. Ferroptosis is a new type of iron dependent cell death, which is different from apoptosis, necrosis, autophagy and other typical cell death. The etiology and mechanism of IR are very complex, and it is not clear yet. At present, more and more studies have proved that Ferroptosis is related to diabetes and its multiple complications [2], but only a few studies have explored the relationship between Ferroptosis and IR, and its direct relationship has not yet been clear. Based on the mechanism of both, this paper reviews the relevant literature and reviews the latest consensus of Ferroptosis and IR to increase the understanding of IR and Ferroptosis, hoping to lay a foundation for further clarifying the mechanism of IR.

## 2. Ferroptosis

Ferrotosis is a process in which iron dependent lipid peroxides accumulate and eventually lead to cell death, which was first proposed by Dixon et al. in 2012. FERROPTOSIS is different from typical cell death modes such as apoptosis, necrosis and autophagy in terms of mode of action, biochemical characteristics and genetic factors [3]. Its characteristics are mainly reflected in morphological and biochemical changes. The morphological changes are mainly reflected in the mitochondria. The mitochondria shrink obviously, the mitochondrial membrane density increases and the outer membrane breaks, and the mitochondrial crista decreases or disappears [3]. Biochemical changes are mainly due to

the inhibition of the depletion of the cystine/glutamate antiporter system (system Xc<sup>-</sup>) on the cell membrane, which causes the depletion of reduced glutathione (GSH) and glutathione peroxidase 4 (GPX4) in the cells, leading to a large amount of deposition of iron and lethal reactive oxygen species (ROS) [4-5].

### **2.1 Regulatory Mechanism of Ferroptosis**

The regulatory mechanism of Ferroptosis is mainly the process of production and elimination of intracellular lipid peroxidation. Iron in cells and ROS and lipid peroxides produced by iron release can promote the occurrence of Ferroptosis. GPX4 can reverse regulate Ferroptosis by eliminating iron, ROS and lipid peroxides. When cells are unable to effectively remove excess ROS in cells through antioxidant mechanism, the accumulated oxidative lipids will induce Ferroptosis [5]. The physiological processes involved in regulating Ferroptosis mainly include iron, lipid and amino acid metabolism.

#### **2.1.1 Iron Metabolism**

Iron is an essential trace element for human body, which plays an important role in metabolism, energy production, DNA synthesis and other cellular levels, as well as in physiological and pathological processes in human body such as oxygen transport. Normally, the iron inside and outside the cell is coordinated and balanced through a special transport system and membrane carriers. Cells can control the intake, excretion, storage and transformation of iron to maintain normal iron homeostasis. Iron in cells exists in two forms: Fe<sup>2+</sup> and Fe<sup>3+</sup>. The iron in food is mainly Fe<sup>3+</sup>, which combines with transferrin, enters cells through Transferrin Receptor 1 (TFR1) on the membrane, and is reduced to Fe<sup>2+</sup> in cells [6]. Fe<sup>3+</sup> is relatively stable as a form of iron storage and transportation. Fe<sup>2+</sup> dissociates in the cytoplasm or combines with serum ferritin to form an iron pool. Ferritin in the iron pool (composed of two subunits of ferritin heavy chain and ferritin light chain, which are encoded by corresponding genes respectively [7]) can be encapsulated by autophagic lysosome under the guidance of nuclear receptor coactivator 4 (NCOA4), and then degraded and released a large amount of Fe<sup>2+</sup> [8], which is called ferritin autophagy [9]. Fe<sup>2+</sup> can participate in oxygen reaction and generate hydroxyl free radicals and hydrogen peroxide and other reactive oxygen species through Fenton chemical reaction. These reactive oxygen species and lipid peroxidation can induce iron death [10].

#### **2.1.2 Lipid Metabolism**

ROS is a group of active oxygen clusters with partial reducing oxygen, including peroxides, superoxide, singlet oxygen, free radicals, etc. They can cause cell death mainly by damaging DNA, RNA and lipid molecules [11]. The accumulation of ROS is the key link to induce Ferroptosis. Lipid peroxides, especially phospholipid peroxides, are the final executors leading to Ferroptosis. The accumulation of lipid peroxides is considered to be a landmark event of Ferroptosis [12]. The presence of polyunsaturated fatty acids (PUFAs), especially arachidonic acid (AA) and adrenic acid (AdA), react with phosphatidylethanolamine (PE) under the action of special enzymes to generate excessive lipid peroxides, thus inducing Ferroptosis [13-14]. The compound AA/AdA - PE was synthesized from AA and AdA complexes via acyl-CoA synthase long 4 (ACSL4) and Recombinant Lysophosphatidyl choline Acyltransferase 3 (LPCAT3) respectively. Some studies have shown that reducing the expression of ACSL4 and LPCAT3 is helpful to inhibit Ferroptosis [5, 15-16]. Only when GPX4 is directly or indirectly inactivated, the highly oxidative PUFAs (such as AA) in the membrane can induce the development of cellular Ferroptosis [17].

#### **2.1.3 Amino Acid Metabolism**

GPX4 is a GSH dependent peroxidase, which can reduce lipid peroxides (LOOH) to lipid alcohols (L-OH), thus preventing ROS accumulation and inhibiting cell Ferroptosis [17-18]. GSH is a cofactor in the synthesis of GPX4. It is a tripeptide molecule synthesized by cysteine, glutamate and glycine in an ATP dependent form [19], and the synthesis of GPX4 requires two molecules of GSH. Therefore, the level of GSH in cells is crucial to the activity of GPX4. The exchange of extracellular cystine and intracellular glutamic acid depends on system Xc<sup>-</sup>, which is formed through disulfide bond connection between light chain subunit (solid carrier family7A11, SLC7A11 is also called x-CT) and heavy chain subunit (solid carrier family3member2, SLC3A2) [20-21]. Cystine enters cells and is reduced to cysteine to synthesize GSH, thus regulating the downstream lipid peroxidation process. Therefore, cysteine directly restricts the biosynthesis of glutathione [3]. The imbalance of amino acid metabolism caused by inhibition of system Xc<sup>-</sup> will lead to Ferroptosis. Moreover, glutamate itself can also affect the function of system Xc<sup>-</sup>. When the concentration of extracellular glutamate is high enough, it can inhibit system Xc<sup>-</sup>, thus inducing Ferroptosis [22]. Under reducing conditions, cysteine can be directly transported into

cells through the alanine-serine-cysteine (ASC) system, thereby inhibiting iron death [22].

### 3. IR

The essence of IR is insulin mediated glucose metabolism dysfunction, which was first proposed by Himsworth in the 1930s [23]. When insulin resistance occurs, the effector organs of insulin (such as adipose tissue, skeletal muscle and liver) produce lower than normal biological effects on normal dose of insulin. IR is a core mechanism leading to metabolic dysfunction in obesity and diabetes, and is the main cause of T2DM.

#### 3.1 Pathogenesis site of IR

There are three sites that cause IR, namely, the functional defects of insulin receptor pre, receptor and post receptor levels. Among them, the most common site is the functional defect of post receptor level, which refers to the abnormality of transmembrane signal transduction after insulin binds to the receptor. At present, it is found that there are mainly three related signaling pathways: phosphatidylinositol 3 kinase (PI3K) pathway, mitogen activated protein kinase (MAPK) pathway and Cap-Cb1 related protein (CAP/Cb1) pathway [24-25]. The functional defect of insulin receptor pre level means that IR has appeared before insulin has combined with insulin receptor, such as insulin gene mutation, multiple endogenous or exogenous insulin antibodies generated in the body, and rapid insulin degradation [26-27]. Defects at the receptor level can be divided into receptor functional abnormalities (such as the reduction of the number of insulin receptors) and structural functional abnormalities (such as gene mutation) [28].

#### 3.2 Hypothesis of pathogenesis

The etiology and mechanism of IR are very complex and have not been fully elucidated. At present, there are two mainstream hypotheses about the mechanism of IR, namely, inflammatory hypothesis and hypothesis of signal transduction [29].

##### 3.2.1 Inflammatory hypothesis

Many studies have shown that inflammation may be one of the pathogenesis of IR [30-32]. There are two main mechanisms of the inflammation hypothesis. On the one hand, inflammatory factors interfere with the insulin signal transduction system. Some studies have shown that in the case of chronic inflammation, the secretion of inflammatory factors such as IL-TNF-CRP increases in the body, which decreases the rate of the tyrosine phosphorylation of insulin receptor, thereby weakening the biological effect of insulin [33]. And TNF- $\alpha$  can activate C-Jun N-terminal kinase (JNK), and enhance the expression of Ser307 phosphorylation of IRS-1, and reduce the expression of tyrosine phosphorylation of IRS-1, thus causing IR [34]. On the other hand, inflammation leads to endothelial dysfunction [35-36].

##### 3.2.2 Hypothesis of Signal transduction

The signal transduction hypothesis mainly refers to the impairment of insulin signaling pathway. IR is mainly caused by abnormal phosphorylation or insufficient expression of insulin receptor. For example, studies have shown that overexpression of protein kinase C (PKC) can induce phosphorylation of IRS-1 serine, and negative feedback regulates tyrosine phosphorylation of IRS-1 to reduce its expression, thereby weakening signal transduction of PI3K pathway [37-38]. It has also been shown that protein tyrosine phosphatase non receptor type 1 (PTPN1) can phosphorylate tyrosine residues of insulin receptor, leading to the decrease of insulin receptor activity, signal transduction and insulin biological response, thus causing IR [39-40]. Evans et al. found that oxidative stress can activate threonine kinase, block insulin action signal pathway and reduce insulin sensitivity in peripheral tissues to cause IR [41].

##### 3.2.3 Other hypotheses

At present, some studies have shown that obesity [42], leptin resistance [43], vitamin D [44-46], smoking [47], mitochondrial dysfunction [48] and other factors can also cause IR, but the relevant molecular mechanism is still controversial, and the specific mechanism needs further study.

#### 4. The Relationship Between Ferroptosis and IR

At present, the relationship between the mechanism of Ferroptosis and of IR is not clear, but through the above overview, we can find that the mechanisms of both have a lot in common, and more and more studies have proved that Ferroptosis is related to multiple complications of diabetes [49]. How IR causes Ferroptosis and how Ferroptosis affects the occurrence and development of IR have not been fully clarified. Now through the existing research, the relationship between them is analyzed and elaborated from the following aspects.

##### 4.1 Oxidative Stress

Oxidative stress is a pathological state in which the production of active oxides exceeds the clearance and breaks the redox balance. When the blood sugar rises in the body, mitochondria will produce a large amount of ROS, and the mitochondrial function will be damaged, thus causing oxidative stress reaction, which is an important factor in the occurrence of T2DM. In addition, in the high glucose state, antioxidants such as GSH will be consumed in large quantities, which will further lead to the accumulation of ROS. Oxidative stress can activate threonine kinase, block the insulin action signal pathway, and reduce the sensitivity of peripheral tissue to insulin to cause IR [21]. Some studies have shown that, the IR can be improved by removing a large amount of ROS and restoring the balance of oxidation and reduction [50]. The depletion of GPX4 with GSH as substrate and the accumulation of ROS are very important in the mechanism of Ferroptosis. It has also been shown that curcumin and epigallocatechin gallate (EGCG), two polyphenols, as well as quercetin, can protect mouse pancreatic  $\beta$  cells from iron poisoning and Erstin induced Ferroptosis. The mechanism is to act as an iron complexing agent to prevent GSH depletion and lipid peroxidation [51-52]. Ellagic acid (EA) can improve the insulin resistance of HepG2 cells treated with oxidative stress and high glucose through miR-223/keap1-Nrf2 pathway [53].

##### 4.2 Iron Overload

Fat, liver and skeletal muscle are all important organs regulating glucose metabolism. Iron ions can participate in and promote lipid oxidation, especially the oxidation of free fatty acids. The increase of free fatty acid oxidation will reduce the use of glucose in muscle tissue and increase the gluconeogenesis of liver to cause IR [54]. In the regulatory mechanism of Ferroptosis, the large release of  $Fe^{2+}$  is a key link. Moreover, the relationship between IR and iron has been revealed in early studies [55]. It is reported that the accumulation of iron can promote the production of ROS in large quantities, thus causing IR of myocardial cells [56]. There is also a hypothesis that excessive iron storage in the human body will increase the risk of T2DM [57-58]. For example, the mouse model of hereditary hemochromatosis that leads to iron overload shows that iron deposition in skeletal muscle, fatty acid oxidation increases, glucose oxidation decreases, and finally increases IR [59-60]. From the perspective of improving diabetes, some studies have shown that insulin secretion and insulin sensitivity have improved, and blood sugar has also been better controlled after reducing the level of iron storage in the body [61-62]. However, it is not completely reliable to calculate the iron storage in the body by the level of serum ferritin, because ferritin can also increase in inflammation, cancer and liver disease [63]. Therefore, it is still unclear whether the ferritin in the blood is the cause or the result of diabetes.

##### 4.3 Mitochondrial dysfunction

When the structure, quantity and activity of mitochondria change, it will cause mitochondrial dysfunction, which will also lead to IR. Studies have shown that IR caused by abnormally high triglyceride levels in liver and muscle is often accompanied by mitochondrial dysfunction such as decreased mitochondrial oxidation activity and ATP synthesis [64]. The morphological change characteristics of Ferroptosis are also reflected in mitochondria, such as obvious shrinkage of mitochondria, increase of mitochondrial membrane density and rupture of outer membrane, reduction or disappearance of mitochondrial crista, etc. At present, there is still some controversy about the occurrence of IR due to mitochondrial dysfunction. Whether the morphological changes of mitochondria in Ferroptosis have an impact on IR remains to be studied. However, studies have shown that FeS clusters can regulate the iron homeostasis of mitochondria [65]. The accumulation of iron in mitochondria caused by the lack of iron sulfur clusters can further lead to the production of ROS in mitochondria [66], and then Ferroptosis occurs due to the accumulation of lipid peroxidation [67]. This is the focus of current research, which needs to be further studied in the future to determine whether the two are related.

## 5. Conclusion and Perspective

As a new way of programmed cell death, Ferroptosis is different from cell apoptosis, necrosis, and autophagy. It is a kind of cell death caused by iron dependent lipid structure peroxidation through abnormal intracellular iron metabolism. Although there are many studies on Ferroptosis, diabetes and its complications, they are still in the early stage. Most of the studies are just revealing that Ferroptosis occurs in various complications of diabetes. The research on its mechanism is not deep enough, and many problems have not yet been solved. For example, the relationship between IR and Ferroptosis, how Ferroptosis interacts with IR, and these related mechanisms need to be further clarified. Ferroptosis is related to changes in many signaling pathways, and the mechanism of the relationship between Ferroptosis and IR may be different in different tissues. Therefore, it is possible to provide new molecular targets for the prevention and treatment of IR by further studying the mechanism of Ferroptosis and IR and clarifying their related signal pathways.

## Acknowledgments

This study was supported by the National Natural Science Foundation of China (NO.81260661, 81860658,82160701), Guangxi Natural Science Foundation (NO.2018GXNSFAA281168), Guilin Science and Technology Development Program (NO.20140120-1-9,20170109-47,20210227-5), Beijing Medical and Health Foundation (NO. YWJKJHJKYJJ-B184007, YWJKJHJKYJJ-B20197DS, YWJKJHJKYJJ-B20234DS), Beijing Health Alliance Charitable Foundation (KM226002) and Guilin Medical University Scientific Research Projects for Postgraduate Students (GYK2022004).

## References

- [1] Sun H,Saeedi P,Karuranga S,et al.IDF diabetes Atlas:Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.[J].Diabetes research and clinical practice,2021.
- [2] He Jiahui,Li Zhangwang, Xia Panpan,Shi Ao,FuChen Xinxi,Zhang Jing,Yu Peng. Ferroptosis and Ferritinophagy in Diabetes Complications [J]. Molecular Metabolism,2022(prepublish).
- [3] Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron dependent form of nonapoptotic cell death [J]. Cell, 2012, 149(5): 1060–1072.
- [4] Xie Y, Hou W, Song X. et al. Ferroptosis: process and function [J]. Cell Death Differ,2016,23(3):369-379.
- [5] Friedmann Angeli JP, Schneider M, Proneth B, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nat Cell Biol. 2014 Dec;16(12):1180-91.
- [6] Galaris DA and Barbouti Pantopoulos K. Iron homeostasis and oxidative stress: An intimate relationship [J]. Biochim Bio phys Acta Mol Cell Res,2019,1866(12):118535.
- [7] Hentze MW, Muckenthaler MU, Galy B, et al. Two to tango: regulation of Mammalian iron metabolism. Cell, 2010, 142(1): 24-38.
- [8] Ke Y, Qian ZM. Brain iron metabolism: neurobiology and neurochemistry [J]. Prog Neurobiol, 2007, 83(3):149-173.
- [9] Mancias JD, Wang X, Gygi SP, et al. Quantitative proteomics identifies NCOA4 as the cargo receptor mediating ferritinophagy. Nature, 2014, 509(7498): 105-109
- [10] Swaminathan S. Iron Homeostasis Pathways as Therapeutic Targets in Acute Kidney Injury. Nephron. 2018; 140(2):156-159.
- [11] Lin LS, Song J, Song L, et al. Simultaneous fenton-like iron delivery and glutathione depletion by MnO<sub>2</sub>-based nanoagent to enhance chemodynamic therapy. Angew Chem Int Ed Engl, 2018, 57(18): 4902-4906
- [12] D'Herde K, Krysko DV. Ferroptosis: oxidized PEs trigger death. Nat Chem Biol, 2017, 13(1): 4-5
- [13] Müller T, Dewitz C, Schmitz J, et al. Necroptosis and ferroptosis are alternative cell death pathways that operate in acute kidney failure. Cell Mol Life Sci. 2017 Oct;74(19):3631-3645.
- [14] Kagan VE, Mao G, Qu F, et al. Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol. 2017 Jan;13(1):81-90.
- [15] Deng F, Sharma I, Dai Y, et al. Myo-inositol oxygenase expression profile modulates pathogenic ferroptosis in the renal proximal tubule. J Clin Invest. 2019 Nov 1;129(11):5033-5049.
- [16] Venkatachalam MA, Weinberg JM, Kriz W, et al. Failed Tubule Recovery, AKI-CKD Transition, and Kidney Disease Progression. J Am Soc Nephrol. 2015 Aug;26(8):1765-76.
- [17] Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci. 2016 Jun;73(11-12):2195-209.
- [18] Maiorino M, Conrad M, Ursini F. GPx4, lipid peroxidation, and cell death: discoveries,

- rediscoveries, and open issues. *Antioxid Redox Signal*, 2018, 29(1): 61-74
- [19] Stockwell BR, Friedmann Angeli JP, Bayir H, et al. Ferroptosis: a regulated cell death Nexus linking metabolism, redox biology, and disease[J]. *Cell*, 2017, 171(2) : 273-285.
- [20] Bridges RJ, Natale NR, Patel SA. System xc<sup>-</sup> cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS. *Br J Pharmacol*, 2012, 165(1): 20-34.
- [21] Bi J, Yang S, Li L, et al. Metadherin enhances vulnerability of cancer cells to ferroptosis. *Cell Death Dis*. 2019 Sep 17; 10(10):682.
- [22] Doll S, Conrad M. Iron and ferroptosis: A still ill-defined liaison. *IUBMB Life*. 2017 Jun;69(6):423-434.
- [23] Himsworth. Diabetes mellitus: its differentiation into insulin sensitive and insulin insensitive type [J]. *The Lancet*, 1936, 18: 127-130.
- [24] Leibiger B, Moede T, Paschen M, et al. PI3K-C2 $\alpha$  Knock down Results in Rerouting of Insulin Signaling and Pancreatic Beta Cell Proliferation [J]. *Cell Reports*, 2015, 13 (1): 15-22.
- [25] Hu S, Chang Y, Wang J, et al. Fucosylated chondroitin sulfate from *Acaudina molpadioides* improves hyperglycemia via activation of PKB/GLUT4 signaling in skeletal muscle of insulin resistant mice[J]. *Food Funct*, 2013, 4(11): 1639-1646.
- [26] Xiao X, Liu L, Xiao Y, et al. Novel frameshift mutation in the insulin (INS) gene in a family with maturity onset diabetes of the young (MODY) [J]. *Diabetes*, 2019, 11(1) :83-86.
- [27] Xiao Y, Li X, Chao C, et al. Severe insulin resistance due to insulin antibodies[J]. *Diabetes*, 2018, 10(7): 611-613.
- [28] Wei C, Burren CP. Diagnostic and management challenges from childhood, puberty through to transition in severe insulin resistance due to insulin receptor mutations[J]. *Pediatr Diabetes*, 2017, 18 (8): 835-838.
- [29] Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance[J]. *Annual Review of Physiology*, 2010, 72: 219-246.
- [30] Bakhtiyari S, Meshkani R, Taghikhani M, et al. Protein Tyrosine Phosphatase-1B (PTP-1B) Knockdown Improves Palmitate-Induced Insulin Resistance in C2C12 Skeletal Muscle Cells[J]. *Lipids*, 2010, 45(3): 237-244.
- [31] Mauer J, Chaurasia B, Goldau J, et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin[J]. *Nature Immunology*, 2014, 15 (5): 423-430.
- [32] Kitamura H, Kimura S, Shimamoto Y, et al. Ubiquitin-specific protease 2-69 in macrophages potentially modulates meta-inflammation[J]. *Faseb Journal Official Publication of the Federation of American Societies for Experimental Biology*, 2013, 27(12): 4940-4953.
- [33] Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor- $\alpha$ , overexpressed in human fat cells from insulin-resistant subjects [J]. *J Biol Chem*, 2003, 278(46): 45777-45784.
- [34] Bloomgarden ZT. Inflammation and insulin resistance[J]. *Diabetes Care*, 2003, 26(5) : 1619-1623.
- [35] Jurrissen TJ, Olver TD, Winn NC, et al. Endothelial dysfunction occurs independently of adipose tissue inflammation and insulin resistance in ovariectomized Yucatan miniature-swine[J]. *Adipocyte*, 2017, 7(1): 35-44.
- [36] Chen T, Xing J, Liu Y. Effects of telmisartan on vascular endothelial function, inflammation and insulin resistance in patients with coronary heart disease and diabetes mellitus[J]. *Experimental and Therapeutic Medicine*, 2018, 15(1): 909-913.
- [37] Lu H, Bogdanovic E, Yu Z, et al. Combined Hyperglycemia- and Hyperinsulinemia-Induced Insulin Resistance in Adipocytes Is Associated With Dual Signaling Defects Mediated by PKC- $\zeta$ [J]. *Endocrinology*, 2018, 159(4) : 1658-1677.
- [38] Greene MW, Burrington CM, Luo Y, et al. PKC $\delta$  is activated in the liver of obese Zucker rats and mediates diet-induced whole body insulin resistance and hepatocyte cellular insulin resistance[J]. *The Journal of Nutritional Biochemistry*, 2014, 25 (3): 281-288.
- [39] Howard L, Nelson KK, Maciewicz RA, et al. Interaction of the met-alloprotease disintegrins MDC9 and MDC15 with two SH3 domain containing proteins, endophilin I and SH3PX1[J]. *Biol Chem*, 1999, 274(44): 31693-31699.
- [40] Bhakta HK, Paudel P, Fujii H, et al. Oligonol promotes glucose uptake by modulating the insulin signaling pathway in insulin-resistant HepG2 cells via inhibiting protein tyrosine phosphatase 1B[J]. *Arch Pharm Res*, 2017, 40 (11): 1314-1327.
- [41] Evans J L, Goldfine I D, Maddux B A, et al. Are oxidative stress activated signaling pathways mediators of insulin resistance and  $\beta$ -cell dysfunction? [J]. *Diabetes*, 2003, 52: 18.
- [42] Regazzetti C, Peraldi P, Grémeaux T, et al. Hypoxia decreases insulin signaling pathways in adipocytes [J]. *Diabetes*, 2009, 58 (1): 95-10.

- [43] Guzel S, Seven A, Guzel EC, et al. *Visfatin, Leptin and TNF- $\alpha$ : Interrelated Adipokines in Insulin-Resistant Clinical and Subclinical Hypothyroidism*[J]. *Endocrine Research*,2013,38(3): 184-194.
- [44] Jamilian M, Foroozanfard F, Rahmani E, et al. *Effect of Two Different Doses of Vitamin D Supplementation on Metabolic Profiles of Insulin-Resistant Patients with Polycystic Ovary Syndrome*[J]. *Nutrients*, 2017,9( 12).
- [45] von Hurst PR, Stonehouse W, Coad J. *Vitamin D supplementation reduces insulin resistance in South Asiawomen living in New Zealand who are insulin resistantand vitamin D deficient-a randomized,placebo-controlled trial*[J]. *Br J Nutr*; 2010,103(4): 549-555.
- [46] Bennani-Kabchi N, Kehel L, El Bouayadi F, et al. *New model of atherosclerosis in insulin resistant sand rats:hypercholesterolemia combined with D2 vitamin*[J]. *Atherosclerosis*,2000,150( 1) : 55-61
- [47] Tong M, Yu R, Silbermann E, et al. *Differential Contributions of Alcohol and Nicotine-Derived Nitrosamine Ketone (NNK) to White Matter Pathology in the Adolescent Rat Brain*[J]. *Alcohol* , 2015, 50(6): 680-689.
- [48] Petersen K F, Befroy D, Dufour S, et al. *Mitochondrial dysfunction in theelderly: possible role in insulin resistance*[J]. *Science*, 2003,300:1140-1142.3.
- [49] He Jiahui, Li Zhangwang, Xia Panpan, Shi Ao, FuChen Xixi, Zhang Jing, Yu Peng. *Ferroptosis and Ferritinophagy in Diabetes Complications*[J]. *Molecular Metabolism*,2022(prepublish).
- [50] Fridlyand L E, Philpson L H. *Reactive species and Earlymanifestation of insulin resistance in type 2 diabetes* [ J]. *Diabetes Obes Metab*,2006,8:136-145.
- [51] T. Kose, M. Vera-Aviles, P. A. Sharp, and G. O. Latunde-Dada, “Curcumin and (-)-epigallocatechin-3-gallate protect murine MIN6 pancreatic beta-cells against iron toxicity and erastin-induced ferroptosis,” *Pharmaceutics*, vol. 12, no. 1,2019.
- [52] Li D, Jiang C, Mei G, Zhao Y, Chen L, Liu J, Tang Y, Gao C, Yao P. *Quercetin Alleviates Ferroptosis of Pancreatic  $\beta$  Cells in Type 2 Diabetes*. *Nutrients*. 2020 Sep 27;12(10):2954.
- [53] Ding X, Jian T, Wu Y, Zuo Y, Li J, Lv H, Ma L, Ren B, Zhao L, Li W, Chen J. *Ellagic acid ameliorates oxidative stress and insulin resistance in high glucose-treated HepG2 cells via miR-223/keap1-Nrf2 pathway*. *Biomed Pharmacother*. 2019 Feb; 110:85-94.
- [54] Vantighem MC, Girardot C, Boulogne A, et al. *Iron overload and insulin resistance* [J]. *Presse Med*, 2005, 34(19 Pt1):1391-1398.
- [55] Basuli D, Stevens RG, Torti FM, et al. *Epidemiological associations between iron and cardiovascular disease and diabetes*[J]. *Front Pharmacol*,2014,5:117.
- [56] Sung HK, Song E, Jahng JWS, Pantopoulos K, Sweeney G. *Iron induces insulin resistance in cardiomyocytes via regulation of oxidative stress*. *Sci Rep*. 2019 Mar 15;9(1):4668.
- [57] M. Jehn, J. M. Clark, and E. Guallar, “Serum ferritin and riskof the metabolic syndrome in U.S. adults,” *Diabetes Care*,vol. 27, no. 10, pp. 2422–2428, 2004.
- [58] R. C. Cooksey, H. A. Jouihan, R. S. Ajioka et al., “Oxidative stress, beta-cell apoptosis, and decreased insulin secretory capacity in mouse models of hemochromatosis,” *Endocrinology*, vol. 145, no. 11, pp. 5305–5312, 2004.
- [59] D. Basuli, R. G. Stevens, F. M. Torti, and S. V. Torti, “Epidemiological associations between iron and cardiovascular disease and diabetes,” *Frontiers in Pharmacology*, vol. 5, p. 117,2014.
- [60] J. Huang, D. Jones, B. Luo et al., “Iron overload and diabetes risk: a shift from glucose to fatty acid oxidation and increased hepatic glucose production in a mouse model of hereditary hemochromatosis,” *Diabetes*, vol. 60, no. 1, pp. 80–87, 2011.
- [61] K. S. Houshyar, R. Lüdtke, G. J. Dobos et al., “Effects of phlebotomy-induced reduction of body iron stores on metabolic syndrome: results from a randomized clinical trial,” *BMC Medicine*, vol. 10, no. 1, p. 54, 2012.
- [62] J. M. Fernandez-Real, G. Penarroja, A. Castro, F. Garcia-Bragado, I. Hernandez-Aguado, and W. Ricart, “Bloodletting in high-ferritin type 2 diabetes: effects on insulin sensitivity and beta-cell function,” *Diabetes*, vol. 51, no. 4, pp. 1000–1004, 2002.
- [63] W. Wang, M. A. Knovich, L. G. Coffman, F. M. Torti, and S. V. Torti, “Serum ferritin: past, present and future,” *Biochimica et Biophysica Acta*, vol. 1800, no. 8, pp. 760–769, 2010.
- [64] Petersen K F, Befroy D, Dufour S, et al. *Mitochondrial dysfunction in theelderly: possible role in insulin resistance* [ J]. *Science*,2003,300:1140-1142.
- [65] D. Pain and A. Dancis, “Roles of Fe-S proteins: from cofactor synthesis to iron homeostasis to protein synthesis,” *Current Opinion in Genetics & Development*, vol. 38, pp. 45–51, 2016.
- [66] N. P. Mena, P. J. Urrutia, F. Lourido, C. M. Carrasco, and M. T. Núñez, “Mitochondrial iron homeostasis and its dysfunctions in neurodegenerative disorders,” *Mitochondrion*, vol.21, pp. 92–105, 2015.
- [67] J. Du, T. Wang, Y. Li et al., “DHA inhibits proliferation and induces ferroptosis of leukemia cells through autophagy dependent degradation of ferritin,” *Free Radical Biology &Medicine*, vol. 131, pp. 356–369, 2019.